Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure

Journal of Clinical Pharmacology

Volumn 57, Issue 4, 2017, Pages 440-451

  Voors, Adriaan Alexander ^a   Düngen, Hans Dirk ^b   Senni, Michele ^c   Nodari, Savina ^d   Agostoni, Piergiuseppe ^e   Ponikowski, Piotr ^f   Bax, Jeroen J ^g   Butler, Javed ^h   Kim, Raymond J ⁱ   Dorhout, Bernard ^a   Dinh, Wilfried ^j   Gheorghiade, Mihai ^k  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^d University and Civil Hospital of Brescia   (Italy)

^e CENTRO CARDIOLOGICO MONZINO   (Italy)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h STONY BROOK UNIVERSITY   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j BAYER PHARMA AG   (Germany)

^k NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

AV block; cardioprotection; heart failure; neladenoson bialanate; partial adenosine A1 receptor agonist

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; CREATINE KINASE; CYSTATIN; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; METOPROLOL SUCCINATE; MINERALOCORTICOID RECEPTOR; NEBIVOLOL; NELADENOSON BIALANATE; PLACEBO; POTASSIUM; TRIACYLGLYCEROL; TROPONIN T; ADENOSINE A1 RECEPTOR AGONIST;

ADULT; ALLERGIC DISEASE; ALLERGIC EDEMA; ANGINA PECTORIS; APPLICATION SITE PRURITUS; ARTHRALGIA; ARTICLE; ASYMPTOMATIC DISEASE; ATRIOVENTRICULAR CONDUCTION; BRADYCARDIA; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; COMPLETE HEART BLOCK; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; ESTIMATED GLOMERULAR FILTRATION RATE; FATIGUE; FATTY ACID BLOOD LEVEL; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; GASTROINTESTINAL DISEASE; GOUT; HEADACHE; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART PROTECTION; HEART RATE; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KIDNEY DISEASE; KIDNEY FAILURE; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; NAUSEA; NEUROLOGIC DISEASE; ORAL PARESTHESIA; ORTHOSTATIC HYPOTENSION; PILOT STUDY; POTASSIUM BLOOD LEVEL; PRESYNCOPE; QT PROLONGATION; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SINUS ARREST; SINUS BRADYCARDIA; SPRAIN; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; THROAT IRRITATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; AGED; BLOOD PRESSURE; CHRONIC DISEASE; DRUG EFFECTS; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART MUSCLE CONDUCTION SYSTEM; ORAL DRUG ADMINISTRATION; PARTIAL AGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ADENOSINE A1 RECEPTOR AGONISTS; ADMINISTRATION, ORAL; AGED; BLOOD PRESSURE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG PARTIAL AGONISM; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART CONDUCTION SYSTEM; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SINGLE-BLIND METHOD;

EID: 85003828515     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.828     Document Type: Article

References (24)

1. Albrecht-Kupper BE, Leineweber K, Nell PG. Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal. 2012;8(Suppl 1):91-99.
2. Greene SJ, Sabbah HN, Butler J, et al. Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Fail Rev. 2016;21(1):95-102.
3. Puhl SL, Kazakov A, Muller A, et al. Adenosine A1 receptor activation attenuates cardiac hypertrophy and fibrosis in response to alpha1 -adrenoceptor stimulation in vivo. Br J Pharmacol. 2016;173(1):88-102.
4. Bulluck H, Sirker A, Loke YK, Garcia-Dorado D, Hausenloy DJ. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials. Int J Cardiol. 2016;202:228-237.
5. Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53(4):527-552.
6. Mustafa SJ, Morrison RR, Teng B, Pelleg A. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol. 2009;193:161-188.
7. Vallon V, Miracle C, Thomson S. Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail. 2008;10(2):176-187.
8. Lerman BB, Ellenbogen KA, Kadish A, et al. Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans. J Cardiovasc Pharmacol Ther. 2001;6(3):237-245.
9. Tendera M, Gaszewska-Zurek E, Parma Z, et al. The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clin Res Cardiol. 2012;101(7):585-591.
10. Sabbah HN, Gupta RC, Kohli S, et al. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail. 2013;6(3):563-571.
11. Soliman EZ, Alonso A, Misialek JR, et al. Reference ranges of PR duration and P-wave indices in individuals free of cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). J Electrocardiol. 2013;46(6):702-706.
12. Mullane K, Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. J Mol Cell Cardiol. 1995;27(4):1041-1054.
13. Grover GJ, Sleph PG, Dzwonczyk S. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors. Circulation. 1992;86(4):1310-1316.
14. Norton ED, Jackson EK, Virmani R, Forman MB. Effect of intravenous adenosine on myocardial reperfusion injury in a model with low myocardial collateral blood flow. Am Heart J. 1991;122(5):1283-1291.
15. Toombs CF, McGee S, Johnston WE, Vinten-Johansen J. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation. 1992;86(3):986-994.
16. Yao Z, Gross GJ. Glibenclamide antagonizes adenosine A1 receptor-mediated cardioprotection in stunned canine myocardium. Circulation. 1993;88(1):235-244.
17. Ely SW, Mentzer RM Jr, Lasley RD, Lee BK, Berne RM. Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg. 1985;90(4):549-556.
18. Lasley RD, Mentzer RM Jr. Adenosine improves recovery of postischemic myocardial function via an adenosine A1 receptor mechanism. Am J Physiol. 1992;263(5 Pt 2):H1460-H1465.
19. Schweda F, Segerer F, Castrop H, Schnermann J, Kurtz A. Blood pressure-dependent inhibition of renin secretion requires A1 adenosine receptors. Hypertension. 2005;46(4):780-786.
20. Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363(15):1419-1428.
21. Voors AA, Dittrich HC, Massie BM, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol. 2011;57(19):1899-1907.
22. Dhalla AK, Chisholm JW, Reaven GM, Belardinelli L. A1 adenosine receptor: role in diabetes and obesity. Handb Exp Pharmacol. 2009;193:271-295.
23. Shearer J, Severson DL, Su L, Belardinelli L, Dhalla AK. Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo. J Pharmacol Exp Ther. 2009;328(1):306-311.
24. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200.